The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression
Wen Pan
1, 2
,
Kun Qu
3
,
Katrina Meeth
4, 5
,
Jijun Cheng
1, 6
,
Hongdi Ma
7
,
Yan Liao
8
,
Xizhi Wen
9, 10, 11
,
Christine Roden
1, 6
,
Zuzana Tobiasova
12, 13, 14, 15, 16, 17
,
Zheng Wei
12, 13, 14, 15, 16, 17
,
Jun Zhao
12, 13, 14, 15, 16, 17
,
Jun Liu
1, 6
,
Bo Guo
1, 18
,
Sajid Khan
19
,
Marcus Bosenberg
4
,
RICHARD A. FLAVELL
12, 13, 14, 15, 16, 17
,
Jun Lu
1, 6
10
State Key Laboratory of Oncology in South China
|
11
Collaborative Innovation Center for Cancer Medicine, Guangzhou 510060, China
|
12
Department of Immunobiology
14
New Haven
|
15
CT
16
06520
17
Usa
|
Publication type: Journal Article
Publication date: 2017-08-15
scimago Q1
wos Q1
SJR: 12.163
CiteScore: 40.8
Impact factor: 26.3
ISSN: 10747613, 10974180
PubMed ID:
28813659
Infectious Diseases
Immunology
Immunology and Allergy
Abstract
Ten-Eleven-Translocation-2 (Tet2) is a DNA methylcytosine dioxygenase that functions as a tumor suppressor in hematopoietic malignancies. We examined the role of Tet2 in tumor-tissue myeloid cells and found that Tet2 sustains the immunosuppressive function of these cells. We found that Tet2 expression is increased in intratumoral myeloid cells both in mouse models of melanoma and in melanoma patients and that this increased expression is dependent on an IL-1R-MyD88 pathway. Ablation of Tet2 in myeloid cells suppressed melanoma growth in vivo and shifted the immunosuppressive gene expression program in tumor-associated macrophages to a proinflammatory one, with a concomitant reduction of the immunosuppressive function. This resulted in increased numbers of effector T cells in the tumor, and T cell depletion abolished the reduced tumor growth observed upon myeloid-specific deletion of Tet2. Our findings reveal a non-cell-intrinsic, tumor-promoting function for Tet2 and suggest that Tet2 may present a therapeutic target for the treatment of non-hematologic malignancies.
Found
Nothing found, try to update filter.
Found
Nothing found, try to update filter.
Top-30
Journals
|
1
2
3
4
5
6
7
8
9
|
|
|
Cancers
9 publications, 5.92%
|
|
|
Frontiers in Immunology
7 publications, 4.61%
|
|
|
Nature Communications
5 publications, 3.29%
|
|
|
Cancer Science
5 publications, 3.29%
|
|
|
Journal of Clinical Investigation
5 publications, 3.29%
|
|
|
Frontiers in Oncology
4 publications, 2.63%
|
|
|
Immunity
4 publications, 2.63%
|
|
|
Cells
3 publications, 1.97%
|
|
|
International Journal of Molecular Sciences
3 publications, 1.97%
|
|
|
Nature Immunology
3 publications, 1.97%
|
|
|
Journal of Experimental Medicine
3 publications, 1.97%
|
|
|
Biomolecules
2 publications, 1.32%
|
|
|
Frontiers in Cell and Developmental Biology
2 publications, 1.32%
|
|
|
Biochimica et Biophysica Acta - Reviews on Cancer
2 publications, 1.32%
|
|
|
Immunological Reviews
2 publications, 1.32%
|
|
|
Journal of Clinical Oncology
2 publications, 1.32%
|
|
|
EMBO Journal
2 publications, 1.32%
|
|
|
Cancer Research
2 publications, 1.32%
|
|
|
Cancer immunology research
2 publications, 1.32%
|
|
|
Blood
2 publications, 1.32%
|
|
|
Signal Transduction and Targeted Therapy
2 publications, 1.32%
|
|
|
bioRxiv
2 publications, 1.32%
|
|
|
Hematological Oncology
2 publications, 1.32%
|
|
|
Cancer Cell
2 publications, 1.32%
|
|
|
JCI insight
1 publication, 0.66%
|
|
|
DMM Disease Models and Mechanisms
1 publication, 0.66%
|
|
|
Bioscience Reports
1 publication, 0.66%
|
|
|
Shock
1 publication, 0.66%
|
|
|
Circulation
1 publication, 0.66%
|
|
|
1
2
3
4
5
6
7
8
9
|
Publishers
|
5
10
15
20
25
30
35
|
|
|
Springer Nature
33 publications, 21.71%
|
|
|
Elsevier
26 publications, 17.11%
|
|
|
MDPI
18 publications, 11.84%
|
|
|
Frontiers Media S.A.
16 publications, 10.53%
|
|
|
Wiley
15 publications, 9.87%
|
|
|
American Society for Clinical Investigation
6 publications, 3.95%
|
|
|
Cold Spring Harbor Laboratory
6 publications, 3.95%
|
|
|
American Association for Cancer Research (AACR)
5 publications, 3.29%
|
|
|
American Society of Clinical Oncology (ASCO)
3 publications, 1.97%
|
|
|
American Society of Hematology
3 publications, 1.97%
|
|
|
Rockefeller University Press
3 publications, 1.97%
|
|
|
Ovid Technologies (Wolters Kluwer Health)
2 publications, 1.32%
|
|
|
Annual Reviews
2 publications, 1.32%
|
|
|
European Molecular Biology Organization
2 publications, 1.32%
|
|
|
The Company of Biologists
1 publication, 0.66%
|
|
|
Baishideng Publishing Group
1 publication, 0.66%
|
|
|
Bentham Science Publishers Ltd.
1 publication, 0.66%
|
|
|
American Physiological Society
1 publication, 0.66%
|
|
|
American Association for the Advancement of Science (AAAS)
1 publication, 0.66%
|
|
|
JMIR Publications
1 publication, 0.66%
|
|
|
Spandidos Publications
1 publication, 0.66%
|
|
|
American Scientific Publishers
1 publication, 0.66%
|
|
|
Science in China Press
1 publication, 0.66%
|
|
|
Tsinghua University Press
1 publication, 0.66%
|
|
|
Oxford University Press
1 publication, 0.66%
|
|
|
5
10
15
20
25
30
35
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.
Are you a researcher?
Create a profile to get free access to personal recommendations for colleagues and new articles.
Metrics
152
Total citations:
152
Citations from 2024:
51
(33.56%)
Cite this
GOST |
RIS |
BibTex |
MLA
Cite this
GOST
Copy
Pan W. et al. The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression // Immunity. 2017. Vol. 47. No. 2. pp. 284-29700000.
GOST all authors (up to 50)
Copy
Pan W., Qu K., Meeth K., Cheng J., Ma H., Liao Y., Wen X., Roden C., Tobiasova Z., Wei Z., Zhao J., Liu J., Guo B., Khan S., Bosenberg M., FLAVELL R. A., Lu J. The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression // Immunity. 2017. Vol. 47. No. 2. pp. 284-29700000.
Cite this
RIS
Copy
TY - JOUR
DO - 10.1016/j.immuni.2017.07.020
UR - https://doi.org/10.1016/j.immuni.2017.07.020
TI - The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression
T2 - Immunity
AU - Pan, Wen
AU - Qu, Kun
AU - Meeth, Katrina
AU - Cheng, Jijun
AU - Ma, Hongdi
AU - Liao, Yan
AU - Wen, Xizhi
AU - Roden, Christine
AU - Tobiasova, Zuzana
AU - Wei, Zheng
AU - Zhao, Jun
AU - Liu, Jun
AU - Guo, Bo
AU - Khan, Sajid
AU - Bosenberg, Marcus
AU - FLAVELL, RICHARD A.
AU - Lu, Jun
PY - 2017
DA - 2017/08/15
PB - Elsevier
SP - 284-29700000
IS - 2
VL - 47
PMID - 28813659
SN - 1074-7613
SN - 1097-4180
ER -
Cite this
BibTex (up to 50 authors)
Copy
@article{2017_Pan,
author = {Wen Pan and Kun Qu and Katrina Meeth and Jijun Cheng and Hongdi Ma and Yan Liao and Xizhi Wen and Christine Roden and Zuzana Tobiasova and Zheng Wei and Jun Zhao and Jun Liu and Bo Guo and Sajid Khan and Marcus Bosenberg and RICHARD A. FLAVELL and Jun Lu},
title = {The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression},
journal = {Immunity},
year = {2017},
volume = {47},
publisher = {Elsevier},
month = {aug},
url = {https://doi.org/10.1016/j.immuni.2017.07.020},
number = {2},
pages = {284--29700000},
doi = {10.1016/j.immuni.2017.07.020}
}
Cite this
MLA
Copy
Pan, Wen, et al. “The DNA Methylcytosine Dioxygenase Tet2 Sustains Immunosuppressive Function of Tumor-Infiltrating Myeloid Cells to Promote Melanoma Progression.” Immunity, vol. 47, no. 2, Aug. 2017, pp. 284-29700000. https://doi.org/10.1016/j.immuni.2017.07.020.